

Revision date: 15-Dec-2006 Version: 1.1 Page 1 of 5

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Inc
Pfizer Pharmaceuticals Group
Ramsgate Road
235 East 42nd Street
Sandwich, Kent
New York, New York 10017
CT13 9NJ
1-212-573-2222
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

Material Name: Ceruletide Diethylamine for Injection

Trade Name: TAKUS(R)
Chemical Family: Mixture

Intended Use: Pharmaceutical product used for gastrointestinal disorders, diagnostic aid.

2. COMPOSITION/INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS List	%
Mercaptosuccinate	70-49-5	200-736-4	*
Ceruletide Diethylamine	71247-25-1	275-298-0	<0.1
Water for injection	7732-18-5	231-791-2	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

3. HAZARDS IDENTIFICATION

Appearance: Powder with a clear Liquid in glass ampules or vials

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Known Clinical Effects: May cause effects similar to those seen in clinical use including transient diarrhea, nausea and

abdominal pain. May cause low blood pressure and dizziness.

EU Indication of danger: Not classified

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

4. FIRST AID MEASURES

Material Name: Ceruletide Diethylamine for Injection

Revision date: 15-Dec-2006 Version: 1.1

Eye Contact: Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical

attention.

Skin Contact: Remove contaminated clothing and wash exposed area with soap and water. Obtain medical

assistance if irritation occurs.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Page 2 of 5

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other

sulfur-containing compounds.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Avoid inhalation and contact with skin, eye, and clothing. Wash thoroughly after handling.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

No Occupational Exposure Limit (OEL) or Short Term Exposure Limit (STEL) has been identified.

Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Personal Protective Equipment:

Hands: Wear protective gloves when working with large quantities.

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is

possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with

large quantities.

Material Name: Ceruletide Diethylamine for Injection

Revision date: 15-Dec-2006 Version: 1.1

Respiratory protection: Respiratory protection is not expected to be necessary under normal handling conditions;

required only if dust is generated. In dusty conditions use an approved dust mask or more

Page 3 of 5

protection as needed.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Powder Color: No data available.

Molecular Formula: Mixture Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the active ingredient.

Acute Toxicity: (Species, Route, End Point, Dose)

Ceruletide Diethylamine

Rat Subcutaneous LD 50 > 1000 mg/kg Rat Intravenous LD 50 714 mg/kg

Mouse Subcutaneous LD 50 > 1000 mg/kg Mouse Intravenous LD 50 1012 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Ceruletide Diethylamine

35 Day(s) Rat Subcutaneous 3500 mg/kg/day LOEL **Pancreas** 26 Week(s) Rat Intramuscular 2730 µg/kg/day LOEL **Pancreas** 26 Week(s) Dog Intramuscular 2730 µg/kg/day LOEL **Pancreas**

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Ceruletide Diethylamine

Embryo / Fetal Development Rat Subcutaneous 300 ug/day NOEL Not teratogenic Embryo / Fetal Development Rabbit Intramuscular 300 ug/day NOEL Not Teratogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

Page 4 of 5

Material Name: Ceruletide Diethylamine for Injection

Revision date: 15-Dec-2006 Version: 1.1

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Mercaptosuccinate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
200-736-4

Ceruletide Diethylamine

EU EINECS List 275-298-0

Water for injection

Inventory - United States TSCA - Sect. 8(b)PresentAustralia (AICS):PresentEU EINECS List231-791-2

16. OTHER INFORMATION

Reasons for Revision: Updated Section 13 - Disposal Considerations.

Material Name: Ceruletide Diethylamine for Injection Page 5 of 5
Revision date: 15-Dec-2006 Version: 1.1

Prepared by:Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet